Pre-existing ADA were detected in 11% (28/261 patients) in TRANSCEND, 2% (2/86 patients) in TRANSCEND-CLL, 2% (2/102 patients) in TRANSCEND-FL, 13% (11/87 patients) in TRANSCEND-MCL, 1% (1/89 patients) in TRANSFORM, and 0% (0/51 patients) in PILOT (51). This evidence concerns the gene ADA and B-cell chronic lymphocytic leukemia.